Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 2.96 HKD -1% Market Closed
Market Cap: 2B HKD

Antengene Corporation Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Antengene Corporation Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
PP&E Gross
ÂĄ7.4B
CAGR 3-Years
6%
CAGR 5-Years
13%
CAGR 10-Years
16%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
PP&E Gross
ÂĄ573.1m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
N/A

Antengene Corporation Ltd
Glance View

Market Cap
2B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.78 HKD
Overvaluation 40%
Intrinsic Value
Price

See Also

Back to Top